Sebastian Spindeldreher
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
Journal: Journal of neuroimmunology
Published: March 19, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
Journal: The AAPS journal
Published: March 18, 2022
10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.
Journal: mAbs
Published: February 18, 2020
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Journal: PLoS medicine
Published: January 24, 2020
T cell epitope mapping of secukinumab and ixekizumab in healthy donors.
Journal: mAbs
Published: January 12, 2020
Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes.
Journal: Cellular & molecular immunology
Published: September 13, 2019
A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.
Journal: Journal of immunological methods
Published: August 12, 2019
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
Journal: The Journal of rheumatology
Published: May 27, 2019
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 14, 2019
Last Updated: 09/26/2026